Catégorie : Pharmacologie

Anandamide administration alone and after inhibition of fatty acid amide hydrolase (FAAH) increases dopamine levels in the nucleus accumbens shell in rats, Marcello Solinas et al., 2006

Anandamide administration alone and after inhibition of fatty acid amide hydrolase (FAAH) increases dopamine levels in the nucleus accumbens shell in rats Marcello Solinas, Zuzana Justinova, Steven R. Goldberg and Gianluigi Tanda Journal of Neurochemistry, 2006, 98, 408–419. doi:10.1111/j.1471-4159.2006.03880.x   Abstract Although endogenous cannabinoid systems have been implicated in the modulation of the rewarding effects of abused drugs and food, little is known about the direct effects of endogenous ligands for cannabinoid receptors on brain reward processes. Here we show for the first time that the intravenous administration of anandamide, an endogenous ligand for cannabinoid receptors, and its longer-lasting synthetic analog methanandamide, increase the extracellular dopamine [...]

Lire la suite

Psilocybin – Summary of knowledge and new perspectives, Filip Tylš et al., 2014

Psilocybin – Summary of knowledge and new perspectives Filip Tylš, Tomáš Páleníček, Jiří Horáček European Neuropsychopharmacology, 2014, 24, 342–356 Doi : 10.1016/j.euroneuro.2013.12.006   Abstract Psilocybin, a psychoactive alkaloid contained in hallucinogenic mushrooms, is nowadays given a lot of attention in the scientific community as a research tool for modeling psychosis as well as due to its potential therapeutic effects. However, it is also a very popular and frequently abused natural hallucinogen. This review summarizes all the past and recent knowledge on psilocybin. It briefly deals with its history, discusses the pharmacokinetics and pharmacodynamics, and compares its action in humans and animals. It attempts to describe the mechanism of psychedelic effects [...]

Lire la suite

Reefer Madness : A Case of Cannabis-Induced Psychosis, Matthew C. Ballenberger et al., 2019

Reefer Madness : A Case of Cannabis-Induced Psychosis Matthew C. Ballenberger,  Robert D. Glatter,  Daniel P. Klein,  Steven Mandel, Medscape Psychiatry,  August 15, 2019 Clinical Presentation A 32-year-old woman with a history of iron-deficiency anemia was brought in by ambulance because of altered mental status. The patient's sister and boyfriend reported that 1 day before presentation, the patient had ingested a marijuana edible and a few hours later developed fatigue and nausea, followed by at least 15 episodes of nonbloody, nonbilious, projectile vomiting throughout the night. In the morning, she became very pale, her lips turned blue, and she became stiff, losing consciousness for [...]

Lire la suite

Salvia divinorum : from recreational hallucinogenic use to analgesic and anti-inflammatory action, Ulises Coffeen & Francisco Pellicer, 2019

Salvia divinorum : from recreational hallucinogenic use to analgesic and anti-inflammatory action Ulises Coffeen, Francisco Pellicer Journal of Pain Research, 2019, Volume 12, 1069-1076 DOI: 10.2147/JPR.S188619   Abstract : Salvia divinorum is a herbal plant native to the southwest region of Mexico. Traditional preparations of this plant have been used in illness treatments that converge with inflammatory conditions and pain. Currently, S. divinorum extracts have become popular in several countries as a recreational drug due to its hallucinogenic effects. Its main active component is a diterpene named salvinorin A (SA), a potent naturally occurring hallucinogen with a great affinity to the κ opioid receptors and with [...]

Lire la suite

Survey study of challenging experiences after ingesting psilocybin mushrooms : Acute and enduring positive and negative consequences, Theresa M. Carbonaro et al., 2016

Survey study of challenging experiences after ingesting psilocybin mushrooms : Acute and enduring positive and negative consequences Theresa M. Carbonaro, Matthew P. Bradstreet, Frederick S. Barrett, Katherine A. MacLean, Robert Jesse, Matthew W. Johnson and Roland R. Griffiths Journal of Psychopharmacology, 2016, 1 –11 DOI: 10.1177/0269881116662634 Abstract Acute and enduring adverse effects of psilocybin have been reported anecdotally, but have not been well characterized. For this study, 1993 individuals (mean age 30 yrs; 78% male) completed an online survey about their single most psychologically difficult or challenging experience (worst “bad trip”) after consuming psilocybin mushrooms. Thirty-nine percent rated it among the top five most challenging [...]

Lire la suite

Harm potential of magic mushroom use : A review, Jan van Amsterdam et al., 2011

Harm potential of magic mushroom use : A review Jan van AMSTERDAM, Antoon OPPERTHUIZEN, Wim van den BRINK Regulatory Toxicology and Pharmacology, 2011, 59, 423-429. Doi : 10.1016/j.yrtph.2011.01.006   Abstract In 2007, the Minister of Health of the Netherlands requested the CAM (Coordination point Assessment and Monitoring new drugs) to assess the overall risk of magic mushrooms. The present paper is an updated redraft of the review, written to support the assessment by CAM experts. It summarizes the literature on physical or psychological dependence, acute and chronic toxicity, risk for public health and criminal aspects related to the consumption of magic mushrooms. In the Netherlands, the [...]

Lire la suite

Beta-caryophyllene is a dietary cannabinoid, Jürg Gertsch et al., 2008

Beta-caryophyllene is a dietary cannabinoid Jürg Gertsch, Marco Leonti, Stephan Raduner, Ildiko Racz, Jian-Zhong Chen, Xiang-Qun Xie, Karl-Heinz Altmann, Meliha Karsak and Andreas Zimmer PNAS (Proceedings of the National Academy of Sciences of the USA),  2008, 105, (26), 9099-9104. Doi : 10.1073/pnas.0803601105   Abstract The psychoactive cannabinoids from Cannabis sativa L. and the arachidonic acid-derived endocannabinoids are nonselective natural ligands for cannabinoid receptor type 1 (CB1) and CB2 receptors. Although the CB1 receptor is responsible for the psychomodulatory effects, activation of the CB2 receptor is a potential therapeutic strategy for the treatment of inflammation, pain, atherosclerosis, and osteoporosis. Here, we report that the widespread plant volatile [...]

Lire la suite

Maternal Marijuana Use, Adverse Pregnacy Outcomes and Neonatal Morbidity, Torri D. Metz et al., 2017

Maternal Marijuana Use, Adverse Pregnancy Outcomes and Neonatal Morbidity Torri D. Metz,  Ms Amanda A. Allshouse, Carol J. Rowland Hogue, Robert L. Goldenberg, Donald J. Dudley, Michael W. Varner, Deborah L. Conway,  George R. Saade,  and Robert M. Silver American Journal of Obstetrics and Gynecology, 2017 October ; 217, (4), 478.e1–478.e8. doi :10.1016/j.ajog.2017.05.050   Abstract Background—The NICHD Stillbirth Collaborative Research Network (SCRN) previously demonstrated an association between stillbirth and maternal marijuana use as defined by the presence of 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid (THC) in the umbilical cord homogenate. However, the relationship between marijuana use and perinatal complications in live births is uncertain. Objective—Our aim was to examine if [...]

Lire la suite

An Overview of Galenic Preparation Methods for Medicinal Cannabis, Luigi Romano and Arno Hazekamp, 2018

An Overview of Galenic Preparation Methods for Medicinal Cannabis Luigi Romano and Arno Hazekamp Current Bioactive Compounds, 2018, 14, DOI: 10.2174/1573407214666180612080412   Abstract : In recent years, the Cannabis plant (Cannabis sativa L.) has been rediscovered as a source of new medicines around the world. Despite the fact that a number of registered medicines have been developed on the basis of purified cannabis components, there is a rapid increasing acceptance and use of cannabis in its herbal form. Licensed producers of high quality cannabis plants now operate in various countries including The Netherlands, Canada, Israel, and Australia, and in many US states. The legal availability of [...]

Lire la suite

Medical Marijuana Use in Oncology : A Review, Gianna Wilkie et al., 2016

Medical Marijuana Use in Oncology : A Review Gianna Wilkie,  Bachir Sakr, Tina Rizack JAMA Oncology, 2016, 2, (5), 670-675. doi:10.1001/jamaoncol.2016.0155   IMPORTANCE : Medicinal marijuana use is currently legal in 23 states and the District of Columbia. As more states approve marijuana use for medical indications, physicians will be asked by their patients for more information regarding the risks and benefits of use. This article reviews the history, adverse effects, and proposed mechanisms of action of marijuana and summarizes the available literature regarding symptom relief and therapeutic value in patients with cancer. OBSERVATIONS : Marijuana in oncologymay have potential for use as an antiemetic, for [...]

Lire la suite